the present knowledge on endovascular repair of ruptured abdominal aortic aneurysms (raaa) prevents firm conclusions when to use this method in comparison to open repair. this review article briefly summarizes results from case series, and discusses how to achieve reliable information despite the absence of randomized controlled trials. at present acareful conclusion might be that dedicated centers with an adequate organization and reasonably high volume of abdominal aortic aneurysm (aaa) should use detailed registry protocols to achieve experience and data to create an as reliable basis as possible for future recommendations.
tured AAA (rAAA), potentially reducing the high mortality rate of OR, that commonly ranges 40% (4).
Prospective randomizedcontrolledtrialsshould be the best proof of evidence comparing EVAR and OR also in case of rAAA. Doubts exist, however,whether such trials arereasonable due to problems with inclusion of patients based on unsuitable morphology or persistent hypotension. The only randomized controlled trial (RCT) (5) that so far has been published reported that out of 103 admitted patients, only 32 could be recruited to the study.T he mortality rate wass imilar after OR and EVAR (53%). The Amsterdam Acute Aneurysm Trial (6) has recently presented data on 256 admitted patients, of whom 83 had a proven rAAA. Forty-six percent weres uitable for EVAR, but only 35% weretreated. These figures correspond to previously published series (7, 8, 9) .
RESULTS OF EVAR FOR RAAA
How to evaluate the role of EVAR when RCT do not exist? Results differ reasonably,w ith dedicated centers reporting encouraging results, while others have not been able to show an obvious benefit of EVAR in comparison with OR. The first Cochrane Review (10) concluded that prospective studies had found an at least as good outcome after EVAR as after OR in the treatment of rAAA. An update of this review has re-The prevalence of abdominal aortic aneurysms (AAA) in 65-year-old men is around 7.5% (1). The cumulative risk of ruptured ue to progression of the aneurysm, is estimated at approximately 12% at 5y ears, with larger aneurysm size increasing that risk (2). As elective aneurysm repair is successful in the great majority of cases, every attempt should be made to find the AAA in time for aplanned operation. Screening procedures will undoubtedly reduce the risk of aneurysm rupture, but emergency repair will still be needed.
Endovascular repair (EVAR) of AAA has its place in the elective treatment of AAA, although clear recommendations can not be formulated as yet, due to the relatively short time of follow up. The short term outcome after EVAR, on the other hand, shows asignificantly reduced mortality and shorter hospital stay compared to open repair (OR) (3).
The lesser surgical trauma obtained by EVAR should be an advantage in the treatment of the rup-cently been published (11) , including one RCT,a nd 33 non-randomized case series, of which only 9were prospective. The analysis comprised 891 EVAR cases.
Suitability for EVAR was reported in 15 of the reviewed studies and ranged 34-100%. Mortality rate varied between 0-53% in these series, with zeromortality in small series of 3, 5, 6a nd 11 cases, respectively.I nt he single larger series including 290 cases (12) , the mortality rate was 39%. These authors quoted their OR series, including 5508 cases, among whom the mortality rate was 47%. Contemporary or historical series OR mortality was reported in only 17 of the 34 reviewed publications, and ranged 0-70%.
Length of ICU stay could be found in 10 studies, and was in general significantly shorter after EVAR. Blood loss was compared in nine studies, and was numerically lower after EVAR in all of them, the difference being statistically significant in the six ones wherestatistics was applied.
The conclusion from this systematic review was that EVAR implies an early outcome at least as good as best conventional OR in selected cases. This conclusion still precludes any firm recommendation when to use EVAR to treat rAAA.
SCANDINAVIAN RESULTS
In as eries from Malmo 2003 (13) , 21 patients were reported after EVAR for rAAA, of whom 14 were compared to 23 OR cases. Thirty-day mortality was 29% for EVAR and 35% for OR. The same authors later reported ar etrospective analysis of predictors for outcome after EVAR versus OR, and concluded that patientage, consciousness and hemoglobin value predicted outcome in those cases whereb oth EVAR and OR werefeasible (14) .
Our first series from Orebro(15) included 41 rAAA patients, of whom 15 weretreated with EVAR (36%). All procedures wereinitiated under local anesthesia andanaortic occlusion balloon wasinserted through the femoral artery to stabilize hemodynamics. The 30-day mortality was 13% after EVAR and 46% after OR. Our recent experience during five years has shown an increase of the proportion of patients treated with EVAR to 78%, valid for the last thirdof the period (16) . Local anesthesia as the single method throughout the repair increased to 50% during the last thirdofthe period, and occlusion balloons were only rarely used. Despite these facts, therew as no difference regarding age, sex, proportion of patients refused from surgery,o rp roportion of hypotensive patients during the period. Over all, the 30-day mortality was 43% after OR, 11%a fter EVAR, with an even lower mortality rate during the last thirdofthe period.
SwEDVASC REPORT
During 2006, 1132 AAA repairs werer eported to the Swedvasc Registry from 33 hospitals. Sixteen of these hospitals performed EVAR, in the proportion of 3.5-87%.
Out of 384 acute aneurysm repairs, 56 werep er- 
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formed with EVAR, however,o nly 37 in rAAA. Thirty-day mortality was 11%among the 56 patients. Overall, Swedvasc figures show,considering the fact that EVAR has only been used for the last few years, a3 0-day mortality rate as follows: rAAA (no shock) 18% after EVAR, 23% after OR; rAAA (shock) 29% after EVAR, 46% after OR.
DISCUSSION
Although high level evidence for the use of EVAR for rAAA is missing, and RCT for proof, though an ideal solution (17), most probably will not be performed, thereseem to be advantages in the use of EVAR compared to OR what regards the immediate survival. It is also likely that blood loss, ICU-stay and hospital stay arereduced in conjunction with EVAR compared to OR. Thereisalso increasing information that local anesthesia can be used throughout the procedure, a fact that should be of importance not to induce an even worse hemodynamic situation than already exists.
In order to enable as correct conclusions as possible it is thereforeo ft he greatest importance to review what disadvantages arel inked to the EVAR procedure, specifically when treating rAAA. Is it reasonable to perform investigations, usually aC T-scan, required to plan for EVAR, in hemodynamically unstable patients? Experience shows that am ajority of thesepatients areunstable just to acertain level, systolic blood pressuremay stay around 80 mmHg, but is not further reduced. In such cases, and with an expeditious organization, av ery rapid investigation may be fully acceptable. Obviously this is not true for patients almost without measurable blood pressure and in deep shock. It should also be mentioned that with evolving technology,i nvestigations at the OR, including intravascular ultrasound (IVUS), may increase the opportunity to take careo fm orep atients even quicker.
Another important issue is the organization required to cover an EVAR service during 24 hours around the year.Sofar,EVA Rismuch moredemanding than OR and the need for skilled stafft oh andle fluoroscopy,g uide wires, stent grafts, IVUS, and all equipment that is not used for open surgery is evident. Most probably this will not be possible in more than al imited number of hospitals, and economic issues will have to be addressed, as the cost for treatment will increase. On the other hand, costs for ICU and hospital carewill be considerably reduced.
well known complications after OR for rAAA are renal insufficiency,g ut ischemia, and the cause of postoperative death is not uncommonly multiorgan failure. It seems that this kind of severecomplication is considerablyreduced after EVAR, butthe question remains, whether this kind of treatment causes other complications, increasing morbidity and secondary mortality.Anobvious issue is the risk for an increased abdominal pressurec ausing ac ompartment syndrome, based on the amount of blood that is left retro-and also intraperitoneally.T herei sl imited knowledge about this phenomenon at present, case reports have been presented, and studies areg oing on to further elucidate this potential risk. Awareness of this problem may help to reduce the risk of severe morbidity,a se mptying of the haematoma is possible.
Unfortunately,rather limited information exists on complications after EVAR for rAAA besides hard facts as mortality rates. Specific complications of EVAR areendoleaks and stent graft migration, problems that have been considerable in the past, and have been one reason for frequent follow-up investigations of all patients. This situation has improved as the armamentarium of approved stent grafts has increased, and readily available prostheses for either aortobi-iliac or aorto-uniiliac use areavailable. Type II endoleaks (into the aneurysmal sac) have been a relatively common complication to all EVAR procedures, now regarded less problematic, requiring intervention only with aneurysmal sac enlargement (18) .
Although follow-up investigations including CT scan will be necessary after EVAR for rAAA, the number of examinations maybereduced, as forelective procedures, due to ad ecreasing risk for stent graft-related complications. On theother hand, time will show whethers uch complications will appear morecommonly after acute compared to elective repair,d ue to potentially suboptimal circumstances during the procedure.
whether the potential short-term benefit of endovascular repair for rAAA will sustain long term, or the outcome of EVAR trial 1( 19) will reappear,r emains to be shown.
COMMENTS AND CONCLUSIONS
It is far from good when surgical methods are gaining broad acceptance without firm proof that ultimately is achieved from randomized controlled trials. It is, on the other hand, easy to ask for such proof, but sometimese xtremely difficultt od esign trialst hat fulfill all criteria that are required. Treatment of rAAA involves circumstances that may preclude RCTs, first the problem of selective inclusion, as therei su ndoubtedly variation in the evaluation of morphology, some surgeons accepting aortic neck disease and iliac artery tortuosity that is not accepted by others for EVAR, or variation in the assessment of hemodynamic stability.T herei sa lso the possibility that patients with severec o-morbidity arem oree asily accepted for EVAR than for OR. As discussed, suitability for EVAR ranges 30-100% in the so far published studies. Even with as detailed guidelines as ever possible it seems unrealistic to believe that multicenter trials with fully acceptable inclusion criteria will be performed.
The next best solution is obviously to use registry data, including patients on an intention-to-treat basis, reporting details about inclusion criteria, co-morbidities, surgical and endovascular technical issues, general and specific complications and follow-up. Evidently only ruptured aneurysms should be included, not symptomatic ones operated on as an emergency due to aconsidered risk for rupture. Centers may be approached to use such protocols to achieve as much information as possible to facilitate conclusions when to use EVAR for rAAA.
The next issue is to what extent this treatment can and should be offered to the public. At present it is evident that with the demand for an extremely effective organization, only few centers aree quipped to deal with EVAR for rAAA, and it seems therefore reasonable to only include experienced centers during the phase when all attempts should be made to find out what role EVAR for rAAA should play in the future. In this paper,N orgren and Larzon, search justification for the use of endovascular approach in ruptured abdominal aortic aneurysm repair (EVRAR). The method can be used under local anaesthesia through minimal access, but it leaves large haematomas in the retroperitoneal space that may cause acute compartment syndrome. Another unanswered issueiswhether thereare additive roles of the haematoma left extraluminally and thrombus left intraluminally as both areknown to increase the activation of inflammation and possibly increase risk for thrombotic complications (1). The ÖrebroGroup states that therewas no difference in proportion of patients denied surgery comparing open and endovascular repair.T hat kind of statement is rather simplistic. The primary decision is whether or not to try to save the patient from dying and if the patient is deemed salvageable, secondarily,whether to use open or endovascular approach. If all patients weret reatable by both approaches, the surgeons probably would have chosen endovascular repair for all of them, i.e. treated 41/41 patients endovascularly instead of doing so in 15/41 in acentrewith seemingly good logistical conditions. In reality therea re two different selection mechanisms. Patients who arehaemodynamically stable, and have long necks, both factors associated with improved survival, will be selected to EVRAR. But therei sa lso ag roup of patients who would not have been considered for OR, due to old age, comorbidities, hostile abdomen, etc, that still will be considered for EVRAR. Operating on this second group of patients will contribute to a lack of difference in survival between patients operated on with EVRAR or OR.
The original paper (2) discloses an 18% rejection rate from any repair,anapparent bias towards one or the other mode of treatment depending on the main interest of the operating surgeon, as well as rejection of four patients from EVRAR due to anatomical reasons. This example shows
